Valid

TB/T 3548-2019Strength design and test accreditation specification for rolling stock-General (English PDF)

Preview PDF

This is a limited preview

Buy now to download the full PDF (5 pages)

Need quotation for your management?

Get a formal quotation for TB/T 3548-2019 in 30 minutes.

Issued by

Ministry of Health of the People’s Republic of China

Level / Type

National · Recommended

Issue date

December 3, 2010

Implementation date

June 3, 2012

Scope

TB/T 3548-2019 (Strength design and test accreditation specification for rolling stock-General) is available as an English-translated PDF.

TB/T 3548-2019 — This Part of WS/T 326 specifies the assessment and evaluation methods of inhibiting dental plaque and (or) reducing the gingival inflammation efficacy.

This Part applies to the toothpaste products that claim, through chemical action, inhibiting dental plaque and reducing gum inflammation; and of which the physiochemical properties and health-safety indicators comply with relevant national standards.

The efficacy evaluation of removing or reducing plaque by mechanical scavenging is not within the scope of this Part.

Found what you need?

Document preview — TB/T 3548-2019

National Standard of the People's Republic of China

ICS
11.020
Classification
C 05

Issued by: Ministry of Health of the People’s Republic of China

Contents

  • Foreword...3
  • 1 Scope...4
  • 2 Normative References...4
  • 3 Terms and Definitions...4
  • 4 Efficacy Evaluation...4
  • 5 Clinical Trial Requirements...5

Foreword

WS/T 326-2010 "toothpaste effect evaluation" is divided into the following parts.

- Part 1.General principles;

- Part 2.Guidelines for anti-caries efficacy evaluation;

- Part 3.Guidelines for efficacy evaluation on the control of dental plaque or

gingivitis;

- Part 4.Guidelines for efficacy evaluation on dentin hypersensitivity.

This is part 3 of WS/T 326.

Clinical trials in this Part references to the clinical trial's design principle guidelines

"American Dental Association Scientific Committee - Accreditation Program - Clinical

Trial Program Guide, 2003" that was formulated by American Dental Association

(ADA).

This Part was proposed by Chinese Stomatological Association.

This Part was approved by Ministry of Health of the People's Republic of China.

Drafting organizations of this Part. School of Stomatology of Peking University, Huaxi

School of Stomatology of Sichuan University, School of Stomatology of Peking

University, and School of Stomatology of Shanghai Jiaotong University.

Main drafters of this Part. Cao Caifang, Hu Deyu, Zhang Boxue, Yang Shenhui, Liu

Xuenan, and Shu Chenbin.

Efficacy evaluation of toothpaste -

Part 3.Guidelines for efficacy evaluation on the

control of dental plaque or gingivitis

1 Scope

This Part of WS/T 326 specifies the assessment and evaluation methods of inhibiting

dental plaque and (or) reducing the gingival inflammation efficacy.

This Part applies to the toothpaste products that claim, through chemical action,

inhibiting dental plaque and reducing gum inflammation; and of which the

physiochemical properties and health-safety indicators comply with relevant national

standards. The efficacy evaluation of removing or reducing plaque by mechanical

scavenging is not within the scope of this Part.

2 Normative References

The following document is essential for the application of this document. For the

documents cited with dates, only that edition applies to this document. For undated

references, the latest edition (including any amendments) applies to this document.

WS/T 326.1 Efficacy evaluation of toothpaste - Part 1.General principles

3 Terms and Definitions

The terms and definitions defined in Part 1 of WS/T 326 apply to this document.

4 Efficacy Evaluation

4.1 in two independent clinical trials, the experimental group is compared with the

control group; when the amount of plaque is reduced and statistically significant, then

it indicates that the subject product having inhibiting plaque efficacy.

4.3 When it meets 4.1 and 4.2 at the same time, it indicates that the product meet

the requirements when determining the effect, that the product has the efficacy to

inhibit plaque and (or) reduce the gingival inflammation.

5 Clinical Trial Requirements

5.1 Test Design Principles

5.1.1 It shall adopt the randomized, controlled, blind-design clinical trial method.

When products that contain certain active ingredients is validated for efficacy for the

first time, it shall be implemented at least two independent clinical trials.

5.1.4 When there are two (or more) examiners to participate in the trial, it shall adopt a

unified standard through calibration test (based on a more-experienced doctor as the

standard); Kappa value shall be above 0.6.If there is only one examiner, he/she shall

conduct, before the test, standard compliance rate test.

5.1.5 Control group may be another group of people whose age, sex, plaque and

gingivitis degree are similar to the conditions of experimental group; it may also take

the cross-repeat test of the testees; that is, testees are randomly grouped; use the

experimental group's products and the control group's products according to a certain

order.

5.1.6 It shall clearly specify the use and dosage of the product. It does not require to

change the brushing method of testees.

5.2 Test duration

5.2.1 For test of reducing plaque, before the test, it needs to conduct scaling to the

testees to remove tartar; on the day when test is started, use a rubber polishing cup to

remove plaque and debris; then start using the product. If it is under the strict

supervision to use the product, then, on the 5th ~ 7th day, it may assess the plaque

volume changes; due to the short period, it may adopt crossover experimental,

however, it must ensure the adequate washout period.

5.3 Experimental testees

5.3.1 Testees' selection

Testees are adult male and female who met the inclusion and exclusion criteria of

suffering from gingival inflammation; it shall be determined according to product

efficacy. The number of test people shall be estimated based on statistical methods

(meet enough statistical power (beta = 0.80) and 95% confidence level), however, the

number of cross-experiment people shall not be less than 30 people.

5.3.2 Inclusion criteria
5.3.3 Exclusion criteria

5.4 Examination indicators

5.4.1 Adopt the plaque index (such as Turesky and other modified Quigley-Hein PI) to

record plaque coverage area and thickness. It shall focus to observe the plaque near

the gingival and interproximal area.

5.4.2 It shall check and record the full-mouth all teeth; each tooth shall be checked at

six sites (buccal-mesial, buccal-central, buccal-distal, lingual-mesial, lingual-central,

and lingual-distal).

WS/T 326.3-2010

WS

HEALTH INDUSTRY STANDARD OF THE

PEOPLE'S REPUBLIC OF CHINA

ICS 11.020

C 05

Efficacy evaluation of toothpaste -

Part 3.Guidelines for efficacy evaluation on

the control of dental plaque or gingivitis

Issued on. DECEMBER 3, 2010

Implemented on. JUNE 3, 2012

Issued by. Ministry of Health of the People's Republic of China

Table of Contents

Foreword... 3

1 Scope... 4

2 Normative References... 4

3 Terms and Definitions... 4

4 Efficacy Evaluation... 4

5 Clinical Trial Requirements... 5

Foreword

WS/T 326-2010 "toothpaste effect evaluation" is divided into the following parts.

- Part 1.General principles;

- Part 2.Guidelines for anti-caries efficacy evaluation;

- Part 3.Guidelines for efficacy evaluation on the control of dental plaque or

gingivitis;

- Part 4.Guidelines for efficacy evaluation on dentin hypersensitivity.

This is part 3 of WS/T 326.

Clinical trials in this Part references to the clinical trial's design principle guidelines

"American Dental Association Scientific Committee - Accreditation Program - Clinical

Trial Program Guide, 2003" that was formulated by American Dental Association

(ADA).

This Part was proposed by Chinese Stomatological Association.

This Part was approved by Ministry of Health of the People's Republic of China.

Drafting organizations of this Part. School of Stomatology of Peking University, Huaxi

School of Stomatology of Sichuan University, School of Stomatology of Peking

University, and School of Stomatology of Shanghai Jiaotong University.

Main drafters of this Part. Cao Caifang, Hu Deyu, Zhang Boxue, Yang Shenhui, Liu

Xuenan, and Shu Chenbin.

Efficacy evaluation of toothpaste -

Part 3.Guidelines for efficacy evaluation on the

control of dental plaque or gingivitis

1 Scope

This Part of WS/T 326 specifies the assessment and evaluation methods of inhibiting

dental plaque and (or) reducing the gingival inflammation efficacy.

This Part applies to the toothpaste products that claim, through chemical action,

inhibiting dental plaque and reducing gum inflammation; and of which the

physiochemical properties and health-safety indicators comply with relevant national

standards. The efficacy evaluation of removing or reducing plaque by mechanical

scavenging is not within the scope of this Part.

2 Normative References

The following document is essential for the application of this document. For the

documents cited with dates, only that edition applies to this document. For undated

references, the latest edition (including any amendments) applies to this document.

WS/T 326.1 Efficacy evaluation of toothpaste - Part 1.General principles

3 Terms and Definitions

The terms and definitions defined in Part 1 of WS/T 326 apply to this document.

4 Efficacy Evaluation

4.1 in two independent clinical trials, the experimental group is compared with the

control group; when the amount of plaque is reduced and statistically significant, then

it indicates that the subject product having inhibiting plaque efficacy.

4.3 When it meets 4.1 and 4.2 at the same time, it indicates that the product meet

the requirements when determining the effect, that the product has the efficacy to

inhibit plaque and (or) reduce the gingival inflammation.

5 Clinical Trial Requirements

5.1 Test Design Principles

5.1.1 It shall adopt the randomized, controlled, blind-design clinical trial method.

When products that contain certain active ingredients is validated for efficacy for the

first time, it shall be implemented at least two independent clinical trials.

5.1.4 When there are two (or more) examiners to participate in the trial, it shall adopt a

unified standard through calibration test (based on a more-experienced doctor as the

standard); Kappa value shall be above 0.6.If there is only one examiner, he/she shall

conduct, before the test, standard compliance rate test.

5.1.5 Control group may be another group of people whose age, sex, plaque and

gingivitis degree are similar to the conditions of experimental group; it may also take

the cross-repeat test of the testees; that is, testees are randomly grouped; use the

experimental group's products and the control group's products according to a certain

order.

5.1.6 It shall clearly specify the use and dosage of the product. It does not require to

change the brushing method of testees.

5.2 Test duration

5.2.1 For test of reducing plaque, before the test, it needs to conduct scaling to the

testees to remove tartar; on the day when test is started, use a rubber polishing cup to

remove plaque and debris; then start using the product. If it is under the strict

supervision to use the product, then, on the 5th ~ 7th day, it may assess the plaque

volume changes; due to the short period, it may adopt crossover experimental,

however, it must ensure the adequate washout period.

5.3 Experimental testees

5.3.1 Testees' selection

Testees are adult male and female who met the inclusion and exclusion criteria of

suffering from gingival inflammation; it shall be determined according to product

efficacy. The number of test people shall be estimated based on statistical methods

(meet enough statistical power (beta = 0.80) and 95% confidence level), however, the

number of cross-experiment people shall not be less than 30 people.

5.3.2 Inclusion criteria
5.3.3 Exclusion criteria

5.4 Examination indicators

5.4.1 Adopt the plaque index (such as Turesky and other modified Quigley-Hein PI) to

record plaque coverage area and thickness. It shall focus to observe the plaque near

the gingival and interproximal area.

5.4.2 It shall check and record the full-mouth all teeth; each tooth shall be checked at

six sites (buccal-mesial, buccal-central, buccal-distal, lingual-mesial, lingual-central,

and lingual-distal).

......

......
This preview omits tables, figures, formulas and parts of the technical clauses. The complete document — 5 pages — is available in the English PDF.

Referenced standards

How to Download TB/T 3548-2019

  1. 1

    Add to cart

    Click "Download PDF" on this page and choose "Buy this standard". You can add more standards before checkout.

  2. 2

    Checkout

    Enter your email and billing details. Payment is processed securely by Stripe (cards or bank transfer). Prefer bank details? Request a quotation (min. order $300).

  3. 3

    Instant delivery (0–9 sec)

    Delivery is automatic: within seconds of payment you'll receive an email with a secure download link. The link stays valid for 72 hours.

  4. 4

    Invoice included

    A tax invoice is attached to the confirmation email. Need a custom invoice? Contact us.

Related Standards

English PDF
5 pages
Instant delivery (0–9 sec)
Invoice included
View Cart

Secure payment via Stripe

Payments accepted

VisaMastercardAmerican ExpressApple PayGoogle PayStripe

TB/T 3548-2019

$80.00